Abstract
Chronic stable angina is a common condition with a prognosis that is less benign than is generally appreciated. The optimal treatment strategy of this disorder is unclear, and few anti-ischaemic agents have been rigorously tested in prospectively randomised mortality studies. The evidence base for the anti-ischaemic therapy of chronic angina draws upon data ‘borrowed’ from studies in acute coronary syndromes, and from studies in chronic angina using surrogate endpoints such as ambulatory silent ischaemia. Such evidence leads us to believe that anti-ischaemic therapy with β-blockers offers a mortality benefit in chronic angina. In contrast, the mortality benefit of lipid lowering therapy and antiplatelet agents is well proven.
Angioplasty offers no mortality benefit in the treatment of chronic angina, although it is more effective than medical therapy alone for the relief of symptoms. In a few patients with high order proximal coronary disease, coronary bypass surgery offers a distinct mortality advantage compared with medical treatment alone. Most patients, however, do not warrant such an approach, and only require surgery for when they remain symptomatic despite adequate medical therapy. Alternative strategies such as cardiac transplantation, transmyocardial laser revascularisation and spinal cord stimulation are now accepted in a subgroup of patients for the treatment of chronic angina refractory to standard therapy.
Similar content being viewed by others
References
Shaper A, Cook D, Walker M et al. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J 1984; 51: 595–605
Smith W, Kenicer M, Tunstall-Pedoe H, et al. Prevalence of coronary heart disease in Scotland: Scottish heart study. Br Heart J 1990; 64: 295–8
Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J 1995; 73: 193–8
ACIP investigators. Asymptomatic Cardiac Ischaemic Pilot (ACIP) study two year follow-up. Circulation 1997; 95: 2037–43
TIDES investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994; 74: 226–31
Joint Working Party of the British Cardiac Society and Royal College of Physicians of London. Investigation and management of stable angina: revised guidelines 1998. Heart 1999; 81: 546–55
Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394–413
Task Force of the American College of Cardiology and the American Heart Association. Guidelines for the management of patients with chronic stable angina. Circulation 1999; 99: 2829–48
Miranda CP, Lehmann KG, Froelicher VF. Correlation between resting segment depression, exercise testing, coronary angiography and long term prognosis. Am Heart J 1991; 122: 1617–28
Dargie HJ. Guidelines for cardiac exercise testing. Eur Heart J 1993; 14: 969–88
Rosanski A, Berman DS. The efficacy of cardiovascular nuclear medicine exercise studies. Semin Nucl Med 1987; 17: 104–20
Ladenheim ML, Kotier TS, Pollock BH, et al. Incremental prognostic power of clinical history, exercise electrocardiography and myocardial perfusion scintigraphy in patients with suspected coronary disease. Am J Cardiol 1987; 59: 270–7
Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 1988; II: 4–8
Brown KA. Prognostic value of myocardial perfusion imaging: state of the art and new developments. J Nucl Cardiol 1996; 3: 516–37
Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl Med J 1992; 326: 10–6
RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350: 461–8
Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischaemia in patients with coronary artery disease. Circulation 1987; 75: 395–400
Tolins M, Weir EK, Chesler E, et al. ‘Maximal’ drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984; 3: 1051–7
Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–97
Swedish Angina Pectoris Aspirin Trial (SAPAT) group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421–5
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39
Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383–9
Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9
West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolaemia. N Engl J Med 1995; 333: 1301–7
Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6
ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; II: 57–66
β-Blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707–13
Norwegian Multicentre Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7
Beevers DG, Johnston JH, Larkin H. Clinical evidence that beta-adrenoreceptor blockers prevent more cardiovascular complications than other antihypertensive drugs. Drugs 1993; 25: 326–30
Nidorf SM, Parsons RW, Thompson PL, et al. Reduced risk of death at 28 days in patients taking β blocker before admission to hospital with myocardial infarction. BMJ 1990; 300: 71–4
Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. NEJM 1996; 335: 1713–20
Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789–94
Deedwania PC, Carbajal EV. Silent ischaemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990; 81: 748–56
Yeung AC, Barry J, Orav J, et al. Effects of asymptomatic ischaemia on long-term prognosis in chronic stable coronary disease. Circulation 1991; 83: 1598–604
ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischaemia during daily life. Circulation 1994; 90: 762–8
Pepine CJ. β-blockers or calcium antagonists in silent ischaemia. Eur Heart J 1993; 14 Suppl. F: 7–14
TIBBS Investigators. Medical treatment to reduce ischemic burden: the total ischemic burden Bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25: 231–8
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circ 1995; 92: 1326–31
Multicentre Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92
Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (DAVIT-II). Am J Cardiol 1990; 66: 779–85
TIBET study group. Total Ischaemic Burden European Trial (TIBET). Eur Heart J 1996; 17: 104–12
Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris: the Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996; 17: 76–81
GISSI investigators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22
ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85
Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–69
Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–8
Pfeffer MA, Brauwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53
Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disese (EUROPA). Eur Heart J 1998; 19 Suppl. J: J52–5
Pfeffer MA, Domanski M, Rosenberg Y Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 1998; 82: 25H–30H
Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563–70
Bucher HC, Hengstler P, Schindler C, et al. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000; 321: 73–7
Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346: 1184–9
Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of the RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary artery bypass grafting. Lancet 1998; 352: 1419–25
BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–25
Garcia MJ, McNamara PM, Gorden T, et al. Morbidity and mortality in diabetics in the Framingham population study. 16-year follow-up. Diabetes 1974; 23: 105–11
UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular disease complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321: 405–11
UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular disease complications of type 2 diabetes (UKPDS 36). BMJ 2000; 321: 412–9
Naka M, Hiramatsu K, Aizawa T, et al. Silent myocardial ischaemia in non-insulin dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J 1992; 123: 46–52
Pell S, D’Alonzo CA. Factors associated with long term survival of diabetics. JAMA 1970; 214: 1833–40
King III SB, Kosinski AS, Guyton RA, et al. Eight year mortality in the Emory angioplasty versus surgery trial (EAST). J Am Coll Cardiol 2000; 35: 1116–21
BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122–9
BARI Investigators. The effect of previous coronary artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N Engl J Med 2000; 342: 989–97
Transmyocardial Carbon Dioxide Laser Revascularization Study Group. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999; 341: 1021–8
Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999; 341: 1029–36
TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al. Clinical outcome of patients with spinal cord stimulation for therapeutically refractory angina pectoris. Heart 1999; 82: 82–8
Flowthow PG. Sympathectomuy for cardiac decompensation and coronary disease. Surgery 1952; 32: 796–802
Claes G, Drott C, Wettervik C, et al. Angina pectoris treated by thoracoscopic sympathectomy. Cardiovasc Surg 1996; 4: 830–1
Gramling-Babb P, Miller MJ, Reeves ST, et al. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Am Heart J 1997; 133: 648–55
Mulligan MA. The innovative use of a patient-controlled analgesia pump for the management of cardiac angina. J Palliative Care 1998; 14: 47–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Staniforth, A.D. Contemporary Management of Chronic Stable Angina. Drugs & Aging 18, 109–121 (2001). https://doi.org/10.2165/00002512-200118020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200118020-00004